BIOXCEL THERAPEUTICS INC. news, videos and press releases
For more news please use our advanced search feature.
BIOXCEL THERAPEUTICS INC. - More news...
BIOXCEL THERAPEUTICS INC. - More news...
- BioXcel Therapeutics Reports First Quarter 2024 Financial Results
- BioXcel Therapeutics to Report First Quarter 2024 Financial Results on May 9, 2024
- BioXcel Therapeutics Announces Late-Breaking Abstract on Preliminary Findings from Phase 2 Investigator-Sponsored Trial of BXCL701 and KEYTRUDA® in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) Selected for Presentation at 2024 ASCO Annual Meeting
- BioXcel Therapeutics Announces Plan for Evaluating BXCL501 in the At-Home Setting to Expand Its Market Potential
- BioXcel Therapeutics Announces TRANQUILITY In-Care Pivotal Phase 3 Trial Plan With BXCL501 for Agitation Associated With Alzheimer’s Dementia
- BioXcel Therapeutics Announces $25 Million Registered Direct Offering
- BioXcel Therapeutics Announces European Patent Office’s Grant of Patent for Method of Treating Agitation in Dementia Using Sublingual Dexmedetomidine
- BioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2023
- BioXcel Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024
- BioXcel Therapeutics Announces Termination of Proposed Public Offering
- BioXcel Therapeutics Receives FDA Fast Track Designation for BXCL701 for Treatment of Small Cell Neuroendocrine Prostate Cancer (SCNC)
- BioXcel Therapeutics Announces Proposed Public Offering
- BioXcel Therapeutics Announces Completion of Patient Enrollment in Safety Portion of Investigator-Sponsored Phase 2 Relapsed Pancreatic Cancer Trial of BXCL701 in Combination with KEYTRUDA®
- BioXcel Therapeutics Announces USPTO’s Allowance of Patent Application for Method of Treating Agitation in Alzheimer’s Disease Using Oromucosal Formulations of Dexmedetomidine
- BioXcel Therapeutics Hosting Virtual Neuroscience R&D Day Today
- BioXcel Therapeutics Strengthens Clinical Development Leadership to Advance Late-Stage Programs
- BioXcel Therapeutics to Host Virtual Neuroscience R&D Day on Dec. 12, 2023
- BioXcel Therapeutics Aligns with FDA Recommendation for Phase 3 Trial for TRANQUILITY Program, Provides Update on Strategic Financing, and Reports Third Quarter 2023 Financial Results
- BioXcel Therapeutics Reports Positive Overall Survival Results from Single-Arm, Open-Label Phase 2 Trial of BXCL701 in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) of Adenocarcinoma Phenotype
- BioXcel Therapeutics Announces Update on NIDA-funded Trial of BXCL501 (sublingual dexmedetomidine) for Potential Treatment of Opioid Use Disorder (OUD)
- BioXcel Therapeutics to Report Third Quarter 2023 Financial Results on November 14, 2023
- BioXcel Therapeutics Receives Permanent J-Code for IGALMI™ (dexmedetomidine) Sublingual Film from Centers for Medicare & Medicaid Services
- BioXcel Therapeutics Announces Positive Findings from Independent Third Party Audit of Data Integrity at TRANQUILITY II Phase 3 Trial Site
- BioXcel Therapeutics Reports Positive Overall Survival Results from Single-Arm, Open-Label Phase 2 Trial of BXCL701 in Patients with Small Cell Neuroendocrine Prostate Cancer
- BioXcel Therapeutics Provides Update on Recent Developments for Late-Stage Clinical Programs and Expansion of IP Portfolio for IGALMI™ (dexmedetomidine) Sublingual Film
- BioXcel Therapeutics Reports Second Quarter 2023 Financial Results and Announces Strategic Reprioritization
- BioXcel Therapeutics to Report Second Quarter 2023 Financial Results on August 14, 2023
- BioXcel Therapeutics Announces Positive Topline Results From TRANQUILITY II Phase 3 Trial of BXCL501 for Acute Treatment of Alzheimer’s Disease-Related Agitation
- BioXcel Therapeutics to Participate at Two Upcoming Investor Conferences
- BioXcel Therapeutics Announces Promising Topline Results from Part 1 of Pivotal SERENITY III Trial of BXCL501 for At-Home Use in Acute Treatment of Agitation in Bipolar Disorders or Schizophrenia